BioConnect Systems was a medical device company that developed a CE-Marked product for improving dialysis access surgery.
Sector: Life Sciences
Better Life Medical
Better Life Medical is a fully-integrated hearing aid manufacturer developing and commercializing novel digital programmable hearing aid solutions for the Chinese market.
Amphora Medical
Amphora Medical was a medical device technology company developing minimally invasive products to restore the quality of life of people suffering from Overactive Bladder Syndrome.
Accuri Cytometers
Accuri Cytometers was a life sciences tools company that democratized flow cytometry for medical and pharmaceutical research. Accuri Cytometers was acquired by Becton Dickinson.
Vicept Therapeutics
Vicept Therapeutics is a dermatology specialty pharmaceutical company developing a topical prescription product for the treatment of the chronic skin condition, Rosacea. Vicept Therapeutics was acquired by Allergan.
Ultragenyx
Ultragenyx (NASDAQ: RARE) a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases.
Transave
Transave is focused on improving the treatment of serious lung diseases through the company’s next generation, proprietary liposomal delivery technology. Transave was acquired by Insmed Inc.
Topaz Pharmaceuticals
Topaz Pharmaceuticals is a specialty pharmaceutical company developing a topical prescription product, Sklice, for the treatment of head lice. Topaz Pharmaceuticals was acquired by Sanofi.
Tetraphase Pharmaceuticals
Tetraphase (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.
Symbiomix
Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals.